NMS Capital portfolio company Flourish Research announced that it has partnered with ENCORE Research Group, headquartered in Fleming Island, Florida.
ENCORE Research Group is a clinical research organization with eight locations across Northern Florida. Since its inception in 1997, ENCORE has conducted more than 3,200 clinical trials across more than 50 therapeutic areas. ENCORE has expertise across multiple therapeutic areas including cardiology, metabolic, neuroscience, gastroenterology, orthopedics, autoimmune, pediatrics, early phase and infectious disease.
Based in New York City, Flourish Research is a fully integrated clinical trial organization in North America. The company has sites throughout Alabama, California, Florida, Illinois, North Carolina, Pennsylvania and Texas. Flourish has conducted more than 3,700 trials across more than 15 therapeutic areas and more than 60 indications. Flourish Research was formed in 2021 by NMS Capital.
The partnership with ENCORE represents the eleventh addition to Flourish since its formation in 2021 and will complement the Flourish platform through additional scale, a depth of therapeutic experience, as well as key talent. Terms of the transaction were not disclosed.
According to data captured in the LevinPro HC database, this acquisition represents the 18th clinical trial deal of 2024. There were 42 clinical trial transactions announced during 2023, and 30 announced during 2022.
